PLA2G1B

Phospholipase A2 · P04054 · PLA2G1B on Sugi Atlas →

92,273 patent compounds predicted against PLA2G1B, 65,057 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Varespladib (SCHEMBL26726)	1.00	7/20
SCHEMBL91914	0.46	7/20
Varespladib Methyl (SCHEMBL25678)	0.83	6/20
SCHEMBL82569	0.66	6/20
Fumaric Acid (SCHEMBL48773)	0.41	6/20
9,10-Phenanthrenequinone (SCHEMBL43050)	1.00	3/20
SCHEMBL40960	0.87	3/20
Epalrestat (SCHEMBL49048)	0.76	3/20
Epalrestat (SCHEMBL49049)	0.76	3/20
SCHEMBL75643	0.59	3/20
SCHEMBL75644	0.59	3/20
Hydrochloric Acid (SCHEMBL98010)	0.57	3/20
Hydrochloric Acid (SCHEMBL99575)	0.57	3/20
SCHEMBL81693	0.53	3/20
SCHEMBL18844	0.52	3/20
SCHEMBL81692	0.51	3/20
SCHEMBL127209	0.49	3/20
Hydrochloric Acid (SCHEMBL126549)	0.48	3/20
SCHEMBL20979	0.46	3/20
SCHEMBL56388	0.46	3/20

Clinical trials — most relevant to PLA2G1B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL)	PHASE4	COMPLETED
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study	PHASE4	COMPLETED
A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis	PHASE3	COMPLETED
European Celecoxib Trial in Primary Breast Cancer	PHASE3	COMPLETED
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes	PHASE3	UNKNOWN
Montelukast in Parkinson Disease	PHASE2/PHASE3	RECRUITING
Montelukast for Early Life Wheezing	PHASE2/PHASE3	COMPLETED
Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM	PHASE3	COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite	PHASE2/PHASE3	WITHDRAWN
Efficacy and Safety of Carica Papaya in Dengue Fever: A Randomised Clinical Trial	PHASE3	COMPLETED
Lovaza's Effect on the Activation of Platelets	PHASE2	COMPLETED
Fish Oil and Aspirin With Type 2 Diabetes	PHASE2	COMPLETED
Assessment of Coronary Plaque Composition	PHASE1	COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides	PHASE1	COMPLETED
Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide	PHASE1	COMPLETED
Role of PLA2G1B During HIV Infection	nan	UNKNOWN
Plasma Free Fatty Acids Profile As A Diagnostic Tool For Acute Ischemic Stroke	nan	COMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
Mucomyst for Hepatitis C	nan	SUSPENDED
Positron Emission Tomography (PET) to Study Brain Signaling	nan	COMPLETED
LDL-Apheresis for FSGS CardioRenal Outcomes	nan	COMPLETED
Investigation of Lipoxin A4, Annexin A1 and Interleukin-1 Beta Levels in Individuals With Periodontitis.	nan	COMPLETED
PET Imaging of DHA Metabolism	nan	COMPLETED
The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations	nan	COMPLETED
Validation of an Assay to Measure Cyclooxygenase-1 Activity	nan	COMPLETED
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer	nan	COMPLETED
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B	nan	COMPLETED
Computed Tomography and Biomarker Analysis in Diagnosing Coronary Artery Disease in Asymptomatic Patients Who Have Undergone Stem Cell Transplant	nan	COMPLETED
Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers	nan	COMPLETED
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PLA2G1B binder may also engage these)

Protein	Name	Similarity
P00592	—	0.993	P00592 →
Q9Z0Y2	—	0.993	Q9Z0Y2 →
P04055	—	0.988	P04055 →
P06596	—	0.988	P06596 →
P14419	—	0.986	P14419 →
P04416	—	0.985	P04416 →
P00593	—	0.982	P00593 →
P00594	—	0.978	P00594 →
P48076	—	0.969	P48076 →
Q7M334	—	0.967	Q7M334 →
P43434	—	0.965	P43434 →
PLA2G2E	Group IIE secretory phospholipase A2	0.959	landscape →
Q99P27	—	0.959	Q99P27 →
P39878	—	0.956	P39878 →
Q6EER6	—	0.954	Q6EER6 →
Q9WVF6	—	0.953	Q9WVF6 →
PLA2G12B	Group XIIB secretory phospholipase A2-like pr	0.951	landscape →
Q8JFB2	—	0.949	Q8JFB2 →
P24293	—	0.949	P24293 →
Q9QUL3	—	0.948	Q9QUL3 →
P14423	—	0.948	P14423 →
Q71QE8	—	0.947	Q71QE8 →
PLA2G2A	Phospholipase A2, membrane associated	0.947	landscape →
Q6EER3	—	0.947	Q6EER3 →
Q8S8N6	—	0.946	Q8S8N6 →
P20255	—	0.946	P20255 →
PLA2G2C	Putative inactive group IIC secretory phospholipase A2	0.945	landscape →
A8MWY0	—	0.945	A8MWY0 →
Q6EER4	—	0.945	Q6EER4 →
P04056	—	0.945	P04056 →